Delivery Order SPE2DB24D8003-SPE2DB25FJTSL

Award Date 1/28/25
Potential Completion Date 1/29/25
Potential Value $1.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, identified as SPE2DX15D8002|SPE2DX24F2TH4, was issued by the Defense Logistics Agency (DLA) Troop Support Medical division to the prime contractor Dakota Drug, Inc. The contract is for the delivery of VYVANSE 50 MG CAPSULE 100S, a pharmaceutical product, to support U.S. Armed Forces medical operations. The contract has a ceiling value of $1,245.99 and a completion date of October 18, 2023. Dakota Drug, Inc. is a self-certified small disadvantaged business...
This federal contract award, valued at $1,461.18, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 100 units of the medication VYVANSE 30 MG CAPSULE. The contract has a firm fixed price pricing type and an ultimate completion date of August 15, 2024. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This contract...
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBQHW, was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of VYVANSE 30 MG CAPSULE 100S. The contract has a ceiling value of $1,013.63 and a performance period through January 29, 2024. This award is not associated with a set-aside program. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, identified as SPE2DX15D8002, is for the delivery of VYVANSE 40 MG CAPSULE 100S, a pharmaceutical product. The contract has a ceiling value of $2,704.11 and a period of performance through November 1, 2023. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a range of pharmaceutical and medical products...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $6,760.43, is for the delivery of 4,563,150,894 units of the pharmaceutical product VYVANSE 30 MG CAPSULE 100S. The contract type is a Delivery Order with a Firm Fixed Price pricing structure, and the ultimate completion date is December 21, 2023. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4562920866 VYVANSE 20 MG CAPSULE 100S. The contract award ID is SPE2DX15D8002|SPE2DX24F2TX1, with a ceiling value of $1,380.43. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is November 29, 2023. This award is not associated with a set-aside program. Dakota Drug, Inc. holds a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of VYVANSE 70 MG CAPSULE 100S. The firm-fixed-price contract has a ceiling value of $1,054.23 and a period of performance through November 22, 2023. Dakota Drug, Inc. is an established vendor for the DLA, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) to provide a wide range of pharmaceuticals,...
This federal contract award, identified as SPE2DX15D8002|SPE2DX23F2XH9, was granted to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) Troop Support Medical division. The $1,011.24 firm fixed-price delivery order is for the provision of 4560939520 VYVANSE 40 MG CAPSULE 100S, a prescription medication. This contract is not set aside and is part of Dakota Drug, Inc.'s larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA,...
This federal contract award, identified as SPE2DX15D8003|SPE2DX24F7D8Q, was issued by the Defense Logistics Agency (DLA) for the procurement of VYVANSE 40 MG CAPSULE 100S, a pharmaceutical product. The $2,287.07 firm fixed-price delivery order was awarded to Dakota Drug, Inc., a self-certified small disadvantaged business, on May 20, 2024, with a completion date of May 21, 2024. Dakota Drug, Inc. is a key supplier to the DLA's Troop Support Medical division, holding a $999,999,999.00...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is valued at $2,927.72 and covers the delivery of VYVANSE 30 MG CAPSULE 100S, a prescription medication, to support the medical supply chain operations for the U.S. Armed Forces. The contract has an ultimate completion date of May 30, 2024 and...
  • SPE2DB24D8003
    Indefinite Delivery Contract
  • SPE2DB24D8003-SPE2DB25FJTSL
    Delivery Order

This federal contract award, identified as SPE2DB24D8003|SPE2DB25FJTSL, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc. The contract is for the delivery of VYVANSE 30 MG CAPSULE 100S, a pharmaceutical product, with a total ceiling value of $1,899.17 and a period of performance extending through January 29, 2025.

The contract is not set aside and is a Firm Fixed Price Delivery Order. Dakota Drug, Inc. is a self-certified small disadvantaged business registered in the System for Award Management (SAM.gov) and operates as a for-profit Subchapter S corporation. The company specializes in providing pharmaceutical products, medical supplies, and healthcare equipment to the U.S. federal government, with a focus on serving the Department of Defense through the DLA. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00, which allows the company to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations.

Generated 4/29/25, 9:47 AM